Schrodinger Inc Stock

$20.61

0.59% yesterday

Nasdaq, Jun 27, 10:02 pm CET

ISIN

US80810D1037

Symbol

SDGR

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Software / Internet

Industry

Standard software

Overview Dividends Analysts Charts News Strategies

Schrodinger Inc Stock price

$20.61

-65.39 76.03% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.12 0.59%

ISIN

US80810D1037

Symbol

SDGR

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Software / Internet

Industry

Standard software

Key metrics

Basic

Market capitalization

$1.5b

Enterprise Value

$1.0b

Net debt

$-500.3m

Cash

$500.3m

Shares outstanding

73.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

6.56 | 5.86

EV/Sales

4.39 | 3.92

EV/FCF

45.67

P/B

4.05

Financial Health

Equity Ratio

51.19%

Return on Equity

-44.40%

ROCE

-33.37%

ROIC

-154.48%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$230.5m | $258.3m

EBITDA

$-186.4m | $-188.8m

EBIT

$-192.8m

Net Income

$-192.2m | $-197.1m

Free Cash Flow

$22.2m

Growth (TTM | estimate)

Revenue

22.29% | 24.44%

EBITDA

10.86% | 7.05%

EBIT

10.09%

Net Income

-34.29% | -5.32%

Free Cash Flow

113.95%

Margin (TTM | estimate)

Gross

62.61%

EBITDA

-80.89% | -73.11%

EBIT

-83.63%

Net

-83.39% | -76.30%

Free Cash Flow

9.61%

EPS

$-2.64

FCF per Share

$0.30

Short interest

26.10%

Employees

891.00

Rev per Employee

$230.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Schrodinger Inc Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Schrodinger Inc forecast:

12x Buy

80%

3x Hold

20%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Schrodinger Inc forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Schrodinger Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	230 230	22% 22% 100%
- Direct Costs	86 86	16% 16% 37%
Gross Profit	144 144	27% 27% 63%
- Selling and Administrative Expenses	140 140	2% 2% 61%
- Research and Development Expense	197 197	3% 3% 85%
EBITDA	-186 -186	11% 11% -81%
- Depreciation and Amortization	6.31 6.31	21% 21% 3%
EBIT (Operating Income) EBIT	-193 -193	10% 10% -84%
Net Profit	-192 -192	34% 34% -83%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Schrodinger Inc Stock News

Neutral

Business Wire

●

about 22 hours ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. “We are exc...

Neutral

Business Wire

●

11 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the company's common stock to five newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors ...

Positive

Seeking Alpha

●

15 days ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data supports continued development, though competition and high efficacy benchmarks in B-cell malignancies remain challenges. Financially, Schrödinger's software business is growing steadily, with strong ca...

More Schrodinger Inc News

Company Profile

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.

Head office	United States
CEO	Ramy Farid
Employees	891
Founded	1990
Website	www.schrodinger.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now